Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan

This study is a prospective, multicenter, real-world study. There are four cohorts. Cohorts 1-3 include second-line, posterior-line, and neoadjuvant colorectal cancer patients, respectively. Cohort 4 include patients with the exception of those with pancreatic and colorectal cancer. As this study is a real-world investigation, treatment procedures, visit schedules, and examinations will be based on the routine clinical practice of physicians. Through the above cohort, the efficacy and safety of irinotecan liposome are comprehensively observed.

NCT Number	NCT06443307
Lead Sponsor	Peking University
Conditions	Colorectal Cancer, Solid Tumor
Enrollment	933 participants
Start Date	2024-07-15
Primary Completion	2026-07-01 (estimated)
Study Completion	2026-08-01 (estimated)
Updated on ClinicalTrials.gov	2024-06-05